Ningún efecto favorable de la suplementación de cr (III) en el metabolismo de lípidos en Diabetes tipo 2meta-análisis de ensayos clínicos, simple y doble ciego, controlados con placebo.

  1. San Mauro Martín, Ismael
  2. Ruiz León, Ana María
  3. Garicano Vilar, Elena
  4. Collado Yurrita, Luis
  5. Ciudad Cabañas, María José
  6. de Mateo Silleras, Beatriz
  7. Redondo del Río, María de Paz
  8. Camina Martín, María Alicia
Revista:
Journal of Negative and No Positive Results: JONNPR

ISSN: 2529-850X

Año de publicación: 2017

Volumen: 2

Número: 3

Páginas: 101-106

Tipo: Artículo

DOI: 10.19230/JONNPR.1253 DIALNET GOOGLE SCHOLAR lock_openDialnet editor

Otras publicaciones en: Journal of Negative and No Positive Results: JONNPR

Objetivos de desarrollo sostenible

Resumen

Introducción. Diabetes mellitus tipo II es un importante problema de salud mundial cuya prevalencia ha aumentado en los últimos años. Muchos estudios han relacionado los suplementos de cromo con la mejora de la diabetes mellitus tipo 2.Objetivo. Realizar un meta-análisis de ensayos individuales y doble ciego, aleatorizados, controlados con placebo, en los que los participantes diagnosticados de DM tipo 2 o intolerantes a la glucosa fueran suplementados con Cr (III).Métodos. Se llevó a cabo una búsqueda bibliográfica sistemática en bases de datos electrónicas, utilizando los términos de búsqueda: (diabetes) y (cromo), hasta julio de 2016. Los estudios elegibles se limitan a doble o simple ciego, de grupos paralelos,controlados con placebo, ensayos clínicos aleatorios, comparando la suplementación mono Cr o combinada durante al menos 30 días en comparación con placebo, en sujetos diagnosticados de DM tipo 2 o con intolerancia a la glucosa.Resultados. La dosis total de la suplementación con Cr y levadura osciló de 20 a 1000 mg / día, y la duración de la administración de suplementos varió de 30 a 120 días. No se encontró reducción estadísticamente significativa en los niveles de HDL-C (p = 0,63), LDL-C (p = 0,53) y TG (p = 0,34) en comparación con el placebo; con un efecto medio ponderado de -0.44 (95% CI: -2.2 to 1.33) mg/dL, - 1.43 (95% CI: -5.94 to 3.08) mg/dL y -7.43 (95% CI: -22.67 to 7.82) mg/dL, respetivamente.Conclusión. La evidencia de nuestro estudio no sugiere que existen efectos favorables de los suplementos de cromo sobre el control del metabolismo lipídico en pacientes con diabetes tipo II. 

Referencias bibliográficas

  • Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014; 103(2):137–49. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0168822713003859
  • Seuring T, Archangelidi O, Suhrcke M. The Economic Costs of Type 2 Diabetes: A Global Systematic Review. Vol. 33. Springer International Publishing; 2015. p. 811–31.
  • Dunning T. Overview of complementary and alternative medicine and diabetes. Pract Diabetes. 2014; 31(9):381–6. Available from: http://doi.wiley.com/10.1002/pdi.1908
  • Penton. Supplement Business Report 2015. Nutr Bus J. 2015; 318.
  • Scientific Opinion on the risks to public health related to the presence of chromium in food and drinking water. EFSA J. 2014; 12(3):3595. Available from: http://doi.wiley.com/10.2903/j.efsa.2014.3595
  • Vincent JB. Chromium: Is It Essential, Pharmacologically Relevant, or Toxic? In Springer Netherlands; 2013 [cited 2016 Aug 27]. p. 171–98. Available from: http://link.springer.com/10.1007/978-94-007-7500-8_6
  • Liu Y, Cotillard A, Vatier C, Bastard J-P, Fellahi S, Stévant M, et al. A Dietary Supplement Containing Cinnamon, Chromium and Carnosine Decreases Fasting Plasma Glucose and Increases Lean Mass in Overweight or Obese Pre-Diabetic Subjects: A Randomized, Placebo-Controlled Trial. PLoS One. 2015; 10(9):e0138646. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26406981
  • Sharma S, Agrawal RP, Choudhary M, Jain S, Goyal S, Agarwal V. Beneficial effect of chromium supplementation on glucose, HbA1C and lipid variables in individuals with newly onset type-2 diabetes. J Trace Elem Med Biol. 2011; 25(3):149–53. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21570271
  • Paiva AN, Lima JG de, Medeiros ACQ de, Figueiredo HAO, Andrade RL de, Ururahy MAG, et al. Beneficial effects of oral chromium picolinate supplementation on glycemic control in patients with type 2 diabetes: A randomized clinical study. J Trace Elem Med Biol. 2015; 32:66–72. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26302914
  • Costello RB, Dwyer JT, Bailey RL, Association AD, Micronutrients I of M (US) P on, Bailey R, et al. Chromium supplements for glycemic control in type 2 diabetes: limited evidence of effectiveness. Nutr Rev. 2016;74(7):455–68. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27261273
  • Appendix: Jadad Scale for Reporting Randomized Controlled Trials. In: Evidence-based Obstetric Anesthesia [Internet]. Oxford, UK: Blackwell Publishing Ltd; [cited 2016 Jul 24]. p. 237–8. Available from: http://doi.wiley.com/10.1002/9780470988343.app1
  • Whitehead A, Whitehead J. A general parametric approach to the meta-analysis of randomized clinical trials. Stat Med. 1991; 10(11):1665–77. Available from: http://doi.wiley.com/10.1002/sim.4780101105
  • DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177–88. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3802833
  • Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109):629–34. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9310563
  • Jain SK, Kahlon G, Morehead L, Dhawan R, Lieblong B, Stapleton T, et al. Effect of chromium dinicocysteinate supplementation on circulating levels of insulin, TNF-alfa oxidative stress, and insulin resistance in type 2 diabetic subjects: randomized, double-blind, placebo-controlled study. Mol Nutr Food Res. 2012; 56(8):1333–41. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22674882
  • Singer GM, Geohas J. The effect of chromium picolinate and biotin supplementation on glycemic control in poorly controlled patients with type 2 diabetes mellitus: a placebo-controlled, double-blinded, randomized trial. Diabetes Technol Ther. 2006; 8(6):636–43. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17109595
  • Geohas J, Daly A, Juturu V, Finch M, Komorowski JR. Chromium picolinate and biotin combination reduces patherogenic index of plasma in patients with type 2 diabetes mellitus: a placebo-controlled, double-blinded, randomized clinical trial. Am J Med Sci. 2007; 333(3):145–53. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17496732
  • Guimarães MM, Martins Silva Carvalho AC, Silva MS. Chromium nicotinate has no effect on insulin sensitivity, glycemic control, and lipid profile in subjects with type 2 diabetes. J Am Coll Nutr. 2013; 32(4):243–50. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24024769
  • Racek J, Trefil L, Rajdl D, Mudrová V, Hunter D, Senft V. Influence of chromium-enriched yeast on blood glucose and insulin variables, blood lipids, and markers of oxidative stress in subjects with type 2 diabetes mellitus. Biol Trace Elem Res. 2006; 109(3):215–30. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16632892
  • Hosseinzadeh P, Javanbakht MH, Mostafavi S-A, Djalali M, Derakhshanian H, Hajianfar H, et al. Brewer’s Yeast Improves Glycemic Indices in Type 2 Diabetes Mellitus. Int J Prev Med. 2013; 4(10):1131–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24319552
  • Martin J, Wang ZQ, Zhang XH, Wachtel D, Volaufova J, Matthews DE, et al. Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes. Diabetes Care. 2006; 29(8):1826–32. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16873787
  • Kleefstra N, Houweling ST, Bakker SJL, Verhoeven S, Gans ROB, Meyboom-de Jong B, et al. Chromium treatment has no effect in patients with type 2 diabetes in a Western population: a randomized, double-blind, placebo-controlled trial. Diabetes Care. 2007; 30(5):1092– 6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17303791
  • Pei D, Hsieh C-H, Hung Y-J, Li J-C, Lee C-H, Kuo S-W. The influence of chromium chloride-containing milk to glycemic control of patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Metabolism. 2006; 55(7):923–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16784965
  • Gunton JE, Cheung NW, Hitchman R, Hams G, O’Sullivan C, Foster- Powell K, et al. Chromium supplementation does not improve glucose tolerance, insulin sensitivity, or lipid profile: a randomized, placebo- controlled, doubleblind trial of supplementation in subjects with impaired glucose tolerance. Diabetes Care. 2005; 28(3):712–3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15735214
  • Albarracin CA, Fuqua BC, Evans JL, Goldfine ID. Chromium picolinate and biotin combination improves glucose metabolism in treated, uncontrolled overweight to obese patients with type 2 diabetes. Diabetes Metab Res Rev. 2008; 24(1):41–51. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17506119
  • Kleefstra N, Houweling ST, Jansman FGA, Groenier KH, Gans ROB, Meyboom-de Jong B, et al. Chromium treatment has no effect in patients with poorly controlled, insulin-treated type 2 diabetes in an obese Western population: a randomized, double-blind, placebo- controlled trial. Diabetes Care. 2006; 29(3):521–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16505499
  • San Mauro-Martin I, Ruiz-León AM, Camina-Martín MA, Garicano-Vilar E, Collado-Yurrita L, Mateo-Silleras B de, et al. [Chromium supplementation in patients with type 2 diabetes and high risk of type 2 diabetes: a metaanalysis of randomized controlled trials]. Nutr Hosp. 2016; 33(1):27. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27019254
  • Yin R V, Phung OJ. Effect of chromium supplementation on glycated hemoglobin and fasting plasma glucose in patients with diabetes mellitus. Nutr J. 2015; 14:14. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25971249
Fuente de los datos: Dialnet